Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) PT at $62.25

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $62.25.

CLDX has been the subject of a number of recent research reports. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. Citigroup began coverage on Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 price objective for the company. Finally, Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th.

Celldex Therapeutics Stock Performance

CLDX stock opened at $26.77 on Tuesday. The firm has a market cap of $1.78 billion, a PE ratio of -10.42 and a beta of 1.57. The firm’s 50 day moving average price is $27.80 and its 200-day moving average price is $34.00. Celldex Therapeutics has a one year low of $22.93 and a one year high of $53.18.

Insider Activity

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 325 shares in the last quarter. KBC Group NV increased its position in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Celldex Therapeutics by 9.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 638 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.